Highlights
•  Digoxin could reverse drug resistance of gemcitabine in gemcitabine-resistant pancreatic cancer cells.
•  Digoxin significantly inhibited Nrf2 signaling in gemcitabine-resistant pancreatic cancer cells.
•  Digoxin-mediated reversing drug resistance of gemcitabine in gemcitabine-resistant pancreatic cancer cells was Nrf2 dependent.